SOLTI-1805 TOT-HER3 study concept: a window-of-opportunity trial of Patritumab Deruxtecan, a HER3 directed antibody drug conjugate, in patients with early breast cancer
T. Pascual, M. Oliveira, E. Ciruelos, M. Bellet Ezquerra, C. Saura, J. Gavilá, S. Pernas, M. Muñoz, M.J. Vidal, M. Margelí Vila, J.M. Cejalvo, B. González-Farré, M. Espinosa-Bravo, Josefina Cruz, Francisco Javier Salvador-Bofill, Juan Antonio Guerra, Ana María Luna Barrera, Miriam Arumi de Dios, Stephen Esker, Pang-Dian Fan, Olga Martínez-Sáez, Guillermo Villacampa, Laia Paré, J.M Ferrero-Cafiero, P. Villagrasa, A. Prat
Manuscrito
Frontiers in Oncology
2021
TOT-HER3
